Please assess the completion status of the following clinical trial:

Trial Title: Assessment of KAN-101 in Celiac Disease (ACeD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Adults aged 18 to 70 years inclusive~2. Diagnosed with celiac disease based on positive serology (eg, tissue transglutaminase IgA antibody and/or deamidated gliadin peptide IgG) and intestinal histology consistent with ≥ Marsh Type II or with evidence of villous atrophy~3. Has HLA-DQ2.5 genotype (HLA-DQA1\*05 and HLA-DQB1\*02) (homozygotes or heterozygotes)~4. Has followed a GFD for \> 12 months immediately prior to study entry~5. Negative or weak positive for tTG-IgA and negative or weak positive for DGP-IgA/IgG during screening~6. Male or female. Females of childbearing potential must use at least 2 acceptable birth control methods~7. Capable of understanding and complying with protocol requirements~8. Patient understands and has signed the informed consent form~Key Exclusion Criteria:~1. Refractory celiac disease~2. Selective IgA deficiency~3. Positive for HLA-DQ8 (DQA1\*03, DQB1\*0302)~4. Previous treatment with tolerance-inducing therapies for celiac disease~5. Known wheat allergy~6. Part B only: History of hyperacute or prolonged symptoms following gluten exposure~7. Uncontrolled or significant medical conditions (including active infections or chronic hepatitis) which, in the opinion of the Investigator, preclude participation~8. History of dermatitis herpetiformis~9. Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SAD Cohort 1 (Type: EXPERIMENTAL): All enrolled patients will receive one dose of KAN-101 Dose A
- SAD Cohort 2 (Type: EXPERIMENTAL): All enrolled patients will receive one dose of KAN-101 Dose B
- SAD Cohort 3 (Type: EXPERIMENTAL): All enrolled patients will receive one dose of KAN-101 Dose C
- SAD Cohort 4 (Type: EXPERIMENTAL): All enrolled patients will receive one dose of KAN-101 Dose D
- MAD Cohort 5 (Type: EXPERIMENTAL): All randomized patients will receive 3 doses of either KAN-101 Dose A or placebo
- MAD Cohort 6 (Type: EXPERIMENTAL): All randomized patients will receive 3 doses of either KAN-101 Dose B or placebo
- MAD Cohort 7 (Type: EXPERIMENTAL): All randomized patients will receive 3 doses of either KAN-101 Dose C or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).